Document:

EX-10.15

 Exhibit 10.15 

Intellectual Property Assignment Deed 

Medvet Sciences Pty Ltd 

ABN 15 008 089 745 
 and

 Angioblast Systems, Incorporated 

 Table of Contents 

 

									
	 	 	 	  	 	  	Page	 
			
	1.	 	Definitions and interpretation.	  	 	2	  
				
		 	1.1	  	Definitions.	  	 	2	  
				
		 	1.2	  	Interpretation	  	 	6	  
			
	2.	 	Assignment.	  	 	7	  
				
		 	2.1	  	Technology Assignment.	  	 	7	  
				
		 	2.2	  	Materials Assignment.	  	 	8	  
				
		 	2.3	  	No further grant of rights to Materials	  	 	9	  
				
		 	2.4	  	Transfer of Technical Information.	  	 	9	  
				
		 	2.5	  	Non-admission of rights	  	 	9	  
				
		 	2.6	  	Moral Rights.	  	 	9	  
				
		 	2.7	  	Assistance and Power of Attorney.	  	 	10	  
			
	3.	 	Bone and Cartilage Licence Assignment.	  	 	10	  
				
		 	3.1	  	Assignment	  	 	10	  
			
	4.	 	Continuing Obligation	  	 	11	  
			
	5.	 	Cardio Licence and Other Fields.	  	 	11	  
			
	6.	 	Research Licence	  	 	12	  
			
	7.	 	Warranty	  	 	12	  
			
	8.	 	Indemnity	  	 	14	  
			
	9.	 	GST.	  	 	14	  
			
	10.    	 	General.	  	 	14	  
				
		 	10.1	  	Nature of obligations.	  	 	14	  
				
		 	10.2	  	Time of the essence	  	 	14	  
				
		 	10.3	  	Entire understanding.	  	 	14	  
				
		 	10.4	  	No adverse construction	  	 	15	  
				
		 	10.5	  	Further assurances	  	 	15	  
				
		 	10.6	  	No waiver.	  	 	15	  
				
		 	10.7	  	Severability	  	 	15	  
				
		 	10.8	  	Successors and assigns	  	 	15	  
				
		 	10.9	  	No assignment	  	 	15	  
				
		 	10.10	  	Consents and approvals	  	 	15	  

									
				
			10.11		No variation		 	15	  
				
			10.12		Costs		 	15	  
				
			10.13		Duty.		 	16	  
				
			10.14		Governing law and jurisdiction.		 	16	  
				
			10.15		Counterparts		 	16	  
				
			10.16		Conflicting provisions		 	16	  
				
			10.17		Non merger		 	16	  
				
			10.18		Operation of indemnities		 	16	  
				
			10.19		No right of set-off		 	16	  
				
			10.20		Relationship of parties		 	16	  
		
	Schedule 1		 	1	  
		
	Schedule 2		 	1	  

  
 -2- 

 Intellectual Property Assignment Deed 

Date 4th October 2004 

Parties 
 1. Medvet
Sciences Pty Ltd ABN 15 008 089 745 of 38 Payneham Road, Stepney, South Australia, 5069 Australia (Medvet) 
 2. Angioblast
Systems, Incorporated of 279 East, 44th Street, New York, NY 10017 United States of America (Angioblast) 

Background 
 A. Medvet
owns all right title and interest in and to Patent Family 1 and Patent Family 3. 
 B. Medvet owns Patent Family 2 as a tenants in common in
equal shares with Angioblast. 
 C. Subject to the terms of this Deed: 

(a) Medvet has agreed to assign to Angioblast absolutely all its right, title and interest in and to the Intellectual Property Rights
subsisting in the Technology and Materials on the terms of this Deed and subject to the rights (if any) granted to Peter MacCallum Cancer Institute under the PeterMac Research Agreement continuing until the termination of the PeterMac Research
Agreement (whether simply due to the effluxion of time or on any other basis whatsoever). 
 (b) to the extent that Medvet cannot assign to
Angioblast any part of the Technology or Materials, Medvet will grant Angioblast an exclusive, worldwide licence (including the right to sub-licence) to use, exploit and conduct research in relation to that part of the Technology and Materials that
cannot be assigned, in the Other Field on the same terms of the All Fields Licence and subject to the rights (if any) granted to Peter MacCallum Cancer Institute under the PeterMac Research Agreement continuing until the termination of the PeterMac
Research Agreement (whether simply due to the effluxion of time or on any other basis whatever); and 
 (c) to the extent that Medvet cannot
assign or grant an exclusive licence to Angioblast of any part of the Materials, Medvet will grant Angioblast a non-exclusive, worldwide licence (including the right to sub-licence) to use, exploit or conduct research in relation to that part of the
Materials that cannot be assigned or exclusively licensed, in the Other Field on the same terms of the All Fields Licence to the extent that it applies to a non-exclusive licence, and subject to the rights (if any) granted to Peter MacCallum Cancer
Institute under the PeterMac Research Agreement continuing until the termination of the PeterMac Research Agreement (whether simply due to the effluxion of time or on any other basis whatever). 

(d) Medvet has agreed to assign to Angioblast all its right, title and interest in and to the Bone and Cartilage Licence. 

 Operative Provisions 

1. Definitions and interpretation. 

1.1 Definitions. In this Deed: 

All Fields Licence means the licence granted to Angioblast by Medvet by clause 5 of the Deed executed between the parties on
27 July 2004 in the Other Field; 
 Bone and Cartilage Fee will have the same meaning that ‘Fee’ has under the Bone
and Cartilage Licence; 
 Bone and Cartilage Field means the field of bone regeneration and repair and cartilage regeneration and
repair; 
 Bone and Cartilage Licence means the exclusive worldwide licence granted by Medvet to Mesoblast Limited to exploit the
Technology and Materials in the Bone and Cartilage Field executed on or about 28 July 2004 on terms, as amended by the Deed of Amendment executed between Medvet and Mesoblast Limited on or about the date of this Deed, which have been disclosed
to Angioblast; 
 Business Day means a day which is not a Saturday, Sunday, public holiday or bank holiday in South Australia; 

Cardio Fees shall have the same meaning that ‘Fee’ has under the Cardio Licence, notwithstanding the termination of the
Cardio Licence; 
 Cardio Field means cell therapy applications derived from cells expressing markers of mesenchymal precursors
including but not limited to STRO-1 or 3G5 markers in respect of cardiac muscle and blood vessels only. Applications may include, but are not limited to, formation of blood vessels and/or cardiac muscle for tissue repair and/or for the treatment of
ischaemic conditions, cardiovascular, cerebrovascular and peripheral vascular disorders; 
 Cardio Licence means the licence
agreement between Medvet and Angioblast executed between the parties on or about 14 May 2004, to exploit the Technology and Materials in the Cardio Field, as amended by clause 3 of the Deed executed between the parties on 27 July 2004;

 Cells means mesenchymal precursor cells; 

Confidential Information means all information not in the public domain or which entered the public domain subsequent to disclosure in
violation of this Deed including but not limited to: 
 (a) know-how, trade secrets, ideas, concepts, technical and operational
information, scientific or technical processes or techniques, product composition or details owned or used by either party; 

  
 -2- 

 (b) computer records, software, source and object codes, manuals, diagrams, graphs, charts,
projections, specifications, estimates, records, accounts, plans, formulae, designs, drawings, models, methods, techniques, price lists, customer lists, market research information, business and marketing plans and projections, correspondence,
documents and papers of every description, including copies of or extracts from any of the same; 
 (c) information concerning the affairs
or property of either party or any transaction in which either party may be or may have been concerned with or interested in; 
 (d) the
names, addresses and other contact details of any client of either party; 
 (e) information about the terms of this Deed or any other
agreements or arrangements with clients of either party or any other third parties with whom either party has dealings; 
 (f) information
about the business methods of either party; and 
 (g) any information which by its nature or by the circumstances of its disclosure, is or
could reasonably be expected to be regarded as confidential to: 
 (i) either party; or 

(ii) any third party with whose consent or approval either party uses that information; 

Deed means this deed including the recitals, any schedules and any annexures; 

Encumbrance means: 
 (a)
an interest or power reserved in or over an interest in an asset, including any retention of title; 
 (b) an interest or power created or
arising in or over an interest in an asset under a bill of sale, mortgage, charge, lien, pledge, trust or other similar instrument, device or power; or 

(c) any other adverse right, title or interest of any nature, by way of security for the payment of a debt or the performance of any other
obligation, 
 and includes any agreement or arrangement (whether legally binding or not) to grant or create any of the above; 

Improvements To Materials means any improvement to, modifications to, applications of or adaptations of any part of the Materials (as
defined excluding the Improvements To Materials) Medvet or the Institute of Medical and Veterinary Science create, develop or acquire whether now or in the future, including any improvements, modifications, applications or adaptations made through
the licence granted to Medvet under clause 6 in relation to any part of the Materials; 

  
 -3- 

 Improvements To Technology means any improvement to, modifications to, applications of or
adaptations of any part of the Technology (as defined excluding the Improvements To Technology) Medvet or the Institute of Medical and Veterinary Science create, develop or acquire whether now or in the future, including any improvements,
modifications, applications or adaptations made through the licence granted to Medvet under clause 6, in relation to any part of the: 

(a) Technical Information; 

(b) Patent Family 1; 
 (c)
Patent Family 2; 
 (d) Patent Family 3; 

(e) Cells; and 
 (f) all
know-how (including but not limited to the know-how for isolating enriching, culturing and expanding the mesenchymal precursor cells) and Confidential Information associated with (a) to €; 

Intellectual Property Rights means all present and future intellectual and industrial property rights conferred by statute, at common
law or in equity and wherever existing, including: 
 (d) patents, designs, copyright, rights in circuit layouts, plant breeder’s
rights, trade marks, know how, brand names, domain names, inventions, product names, trade secrets and any other rights subsisting in the results of intellectual effort any field, whether or not registered or capable of registration; 

(e) any application or right to apply for registration of any of those rights; 

(f) any registration of any of those rights or any registration of any application referred to in paragraph (b); and 

(g) all renewals and extensions of these rights; 

Materials means hybridomas producing antibodies reactive with a marker expressed by cells of mesenchymal, haemopoietic, keratinocyte or
any other lineage, and any Improvements To Materials; 
 Other Field means all fields outside the Bone and Cartilage Field; 

Patent Family 1 means all rights and interests in and to issued patents and pending patent applications in any country, including all
substitutions, continuations, continuations-in-part, divisional, supplementary protection certificates, renewals, all letters patent granted thereon, and all 

  
 -4- 

 
reissues, re-examinations, extensions, confirmations, revalidations, registrations and patents of addition thereof that result either directly or indirectly from the following patent applications
which are sought and obtained: 
 (a) ‘Mesenchymal Precursor Cell PCT/AU00/00822; 

(b) ‘Mesenchymal Precursor Cell’ Australian Patent Application No. 56636/00; 

(c) ‘Mesenchymal Precursor Cell’ U.S. Patent Application No. 10/030411; 

(d) Continuation-in-Part U.S. Patent Application No.10/813,747; 

(e) ‘Perivascular Mesenchymal Precursor Cells’ PCT/AU2004/00416; and 

(f) U.S. Continuation-in-Part application related to USSN10/030411 titled ‘Mesenchymal Precursor Cell and use thereof in the repair of
bone defects and fractures in mammals’; 
 Patent Family 2 means ‘Perivascular Mesenchymal Precursor Cell Induced Blood
Vessel Formation’ PCT/AU2004/00417 patent and all rights and interests in and to issued patents and pending patent applications in any country, including all substitutions, continuations, continuations-in-part, divisional, supplementary
protection certificates, renewals, all letters patent granted thereon, and all reissues, re-examinations, extensions, confirmations, revalidations, registrations and patents of addition resulting either directly or indirectly from this patent; 

Patent Family 3 means all rights and interests in and to issued patents and pending patent applications in any country, including all
substitutions, continuations, continuations-in-part, divisional, supplementary protection certificates, renewals, all letters patent granted thereon, and all reissues, re-examinations, extensions, confirmations, revalidations, registrations and
patents of addition thereof relating, whether directly or indirectly, to the proliferation of mesenchymal precursor cells and tissue specific committed cells and use thereof: 

(g) to generate cardiac muscle, bone or vascular and endothelial tissue; 

(h) to generate adipose tissue; 

(i) to generate neural and glial tissue; 

(j) to generate smooth muscle tissue; and 

(k) to generate cartilage and ligamentous tissue, 

which are sought and obtained by Medvet; 

  
 -5- 

 PeterMac Research Agreement means the research agreement dated 1 October 1999 between
Medvet and the Inner and Eastern Health Care Network trading as Peter MacCallum Cancer Institute; 
 Protected Country means any
country in which Angioblast is and remains the proprietor or applicant of any patent or patent application in the Technology or any patent or patent application in any Improvements to Technology made or acquired by Angioblast. 

Technical Information means all of the information and know-how concerning the Technology (as defined excluding the Technical
Information) in Medvet’s possession or control at the date of execution of this Deed, including without limitation all laboratory notebooks, research results and information relating to Patent Family 1, Patent Family 2, and Patent Family 3;

 Technology means: 

(h) the Technical Information; 

(i) Patent Family 1; 
 (j)
Patent Family 2; 
 (k) Patent Family 3; 

(l) Improvements To Technology; 

(m) Cells; and 
 (n) all
know-how (including but not limited to the know-how for isolating enriching, culturing and expanding the mesenchymal precursor cells) and Confidential Information associated with (a) to (f); and 

Unprotected Country means any country in the which for any reason (other than a breach of this Deed by Medvet) is not a Protected
Country or at any time ceases to be a Protected Country. 
 1.2 Interpretation. In this Deed, unless the context requires otherwise:

 (a) the singular includes the plural and vice versa; 

(b) a gender includes the other genders; 

(c) the headings are used for convenience only and do not affect the interpretation of this Deed; 

(d) other grammatical forms of defined words or expressions have corresponding meanings; 

  
 -6- 

 (e) a reference to a document includes the document as modified from time to time and any
document replacing it; 
 (f) if something is to be or may be done on a day that is not a Business Day then it must be done on the next
Business Day; 
 (g) the word “person” includes a natural person and any body or entity whether incorporated or not; 

(h) the word “month” means calendar month and the word “year” means 12 months; 

(i) the words “in writing” include any communication sent by letter, facsimile transmission or email or any other form of
communication capable of being read by the recipient; 
 (j) a reference to a thing includes a part of that thing; 

(k) a reference to all or any part of a statute, rule, regulation or ordinance (statute) includes that statute as amended,
consolidated, re-enacted or replaced from time to time; 
 (l) wherever “include” or any form of that word is used, it must be
construed as if it were followed by “(without being limited to)”; 
 (m) money amounts are stated in Australian currency unless
otherwise specified; 
 (n) a reference to any agency or body, if that agency or body ceases to exist or is reconstituted, renamed or
replaced or has its powers or functions removed (defunct body), means the agency or body which performs most closely the functions of the defunct body. 

2. Assignment. 
 2.1
Technology Assignment. 
 (a) In consideration for the payments and acknowledgements contained in clause 4 and 5 and subject to the
rights (if any) granted to Peter MacCallum Cancer Institute under the PeterMac Research Agreement continuing until the termination of the PeterMac Research Agreement (whether simply due to the effluxion of time or on any other basis whatever),
Medvet hereby assigns to Angioblast absolutely and beneficially, such assignment to be effective from the date of execution of this Deed, the whole of its rights, title and interest, whether presently existing or which arises at a date after the
date of this Deed in and to any Intellectual Property Rights subsisting in the Technology including: 
 (i) the right to apply for and
register in any country worldwide such Intellectual Property Rights; and 

  
 -7- 

 (ii) the right to claim (and retain) any damages and other remedies (including but not limited
to an account of profits) for past infringement of and wrongful interference of such Intellectual Property Rights by third parties (whether or not they arose prior to the date this Deed came into effect). 

(Assigned Technology). 

(b) Medvet acknowledges and agrees that Angioblast owns and will own all right, title and interest in and to all of the Assigned Technology
from the date of this Deed, or if acquired, developed or created after the date of this Deed, on the date such Assigned Technology is first acquired, developed or created. 

(c) To the extent that Medvet cannot assign any part of the Technology under clause 2.1(c), (Unassignable Technology),
Medvet grants to Angioblast an exclusive worldwide licence (including the right to sub-licence) to use, exploit and conduct research in relation to the Unassignable Technology in the Other Field on the same terms of the All Fields Licence, such
licence being subject to the rights (if any) granted to Peter MacCallum Cancer Institute under the PeterMac Research Agreement continuing until the termination of the PeterMac Research Agreement (whether simply due to the effluxion of time or on any
other basis whatsoever). 
 2.2 Materials Assignment. 

(a) In consideration for the payments and acknowledgements contained in clause 4 and 5 and subject to the rights (if any) granted to any
third parties in relation to the Materials (including Peter MacCallum Cancer Institute under the PeterMac Research Agreement), Medvet hereby assigns to Angioblast absolutely and beneficially, such assignment to be effective from the date of
execution of this Deed, the whole of its rights, title and interest, whether presently existing or which arises at a date after the date of this Deed in and to any Materials and any Intellectual Property Rights subsisting in the Materials including:

 (i) the right to apply for and register in any country worldwide such Intellectual Property Rights; and 

(ii) the right to claim (and retain) any damages and other remedies (including but not limited to an account of profits) for past
infringement of and wrongful interference of such Intellectual Property Rights by third parties (whether or not they arose prior to the date this Deed came into effect). 

(Assigned Materials). 

(b) Medvet acknowledges and agrees that Angioblast owns and will own all right, title and interest in and to all of the Assigned Materials
from the date of this Deed, or if acquired, developed or created after the date of this Deed, on the date such Assigned Materials is first acquired, developed or created. 

(c) To the extent that Medvet cannot assign any part of the Materials under clause 2.2(a), (Unassignable Materials), Medvet grants to
Angioblast an exclusive worldwide 

  
 -8- 

 
licence (including the right to sub-licence) to use, exploit and conduct research in relation to the Unassignable Materials in the Other Field on the same terms of the All Fields Licence, such
licence being subject to the rights (if any) granted to Peter MacCallum Cancer Institute under the PeterMac Research Agreement and continuing until the termination of the PeterMac Research Agreement whether simply due to the effluxion of time or on
any other basis whatsoever. 
 (d) To the extent that Medvet cannot grant an exclusive licence to any part of the Unassignable Materials
under clause 2.2(c), (Non-Exclusive Unassignable Materials), Medvet grants to Angioblast an non-exclusive worldwide licence (including the right to sub-licence) to use, exploit and conduct research in relation to the Non-Exclusive
Unassignable Materials in the Other Field on the same terms of the All Fields Licence to the extent that it applies to a non-exclusive licence, such licence being subject to the rights (if any) granted to Peter MacCallum Cancer Institute under the
PeterMac Research Agreement and continuing until the termination of the PeterMac Research Agreement whether simply due to the effluxion of time or on any other basis whatsoever. 

(e) Notwithstanding the terms of this clause 2.2, Medvet represents and warrants that it is able to freely assign all of the Materials and
all Intellectual Property Rights in the Materials identified in Schedule 2 (“Essential Materials”) pursuant to clause 2.2(a), and Medvet warrants that the assignment of such Essential Materials will not breach any third party rights
(including the rights granted to the Peter MacCallum Cancer Institute under the PeterMac Research Agreement). 
 2.3 No further grant of
rights to Materials. Medvet acknowledges and agrees that it will not, from the date of this Deed, grant any further rights in relation to the Materials without Angioblast’s prior written consent (such consent to be withheld at the sole and
absolute discretion of Angioblast). 
 2.4 Transfer of Technical Information. 

(a) Medvet will within 30 days from the date of this Deed, provide and deliver all of the Technical Information to Angioblast. 

(b) The parties acknowledge that Medvet is under an obligation to provide copies of all Technical Information to Mesoblast under the Bone and
Cartilage Licence. 
 2.5 Non-admission of rights. Nothing in this Deed constitutes the admission or grant by any of the
parties of any rights to the Technology or Materials to the Peter MacCallum Cancer Institute whether under the PeterMac Research Agreement or otherwise. 

2.6 Moral Rights. 
 (a)
Insofar as any moral rights may exist in any Technology and Materials (Works), Medvet will use its best endeavours to ensure that, to the extent that such consents have not already been obtained, within 60 days of the execution of this Deed,
the authors of such Works irrevocably and unconditionally consent in writing by executing the deed poll in Schedule 1, to the fullest extent permitted by law (whether present or future), pursuant to Part IX of the Copyright Act 1968 (Cth), to
Angioblast, its licensees, assignees and successors and their licensees, and other persons authorised by any of them: 

  
 -9- 

 (i) reproducing, adapting, publishing, performing, exhibiting, communicating or transmitting the
Works or any adaptation thereof (or any part of any of the Works or of any such adaptation) anywhere in the world, in whatever form and in whatever circumstances Angioblast thinks fit including the making of any distortions, additions or alterations
to the Works or any adaptation thereof (or any part of the Works or of such adaptation) as so reproduced, adapted, published, performed, exhibited, communicated or transmitted; and 

(ii) reproducing, adapting, publishing, performing, exhibiting, communicating or transmitting the Works or any adaptation thereof (or any
part of any of the Works or of any such adaptation) anywhere in the world without making identification of Angioblast or Medvet or the authors or any other person in relation thereto. 

2.7 Assistance and Power of Attorney. 

(a) Medvet will render all assistance and execute all documentation necessary to: 

(i) transfer ownership of the Assigned Technology and Assigned Materials to Angioblast; and 

(ii) if necessary confirm any licence granted pursuant to clauses 2.1(c), 2.2(c) and 2.2(d). 

(b) Medvet hereby irrevocably appoints Angioblast and each director and secretary for the time being of Angioblast to be Medvet’s
attorney and in Medvet’s name and on Medvet’s behalf to execute and do all such deeds, acts and things as Angioblast may consider reasonably necessary to give full effect to the assignment and the grant of licences (if any) in clauses 2.1
and 2.2. 
 3. Bone and Cartilage Licence Assignment. 

3.1 Assignment. In consideration for the undertaking contained in clause 4, Medvet: 

(a) hereby assigns to Angioblast: 

(i) all the rights, title and interest of Medvet under the Bone and Cartilage Licence absolutely; and 

(ii) without limiting clause 3.1(a)(i), all rights of action, claims and demands Medvet has arising from or relating to the Bone and
Cartilage Licence; 
 (b) to the extent that Medvet cannot assign any of its duties or obligations under the Bone and Cartilage Licence to
Angioblast, hereby acknowledges and agrees that, subject to Angioblast’s written direction, it will continue to comply with and discharge its obligations under the Bone and Cartilage Licence at Angioblast’s expense; and 

  
 -10- 

 (c) notwithstanding Medvet’s obligations under clause 3.1(b), Medvet hereby irrevocably
appoints Angioblast and each director and secretary for the time being of Angioblast to be Medvet’s attorney in Medvet’s name and on Medvet’s behalf to execute and do all such deeds, acts and things as Angioblast may consider
reasonably necessary to give full effect to this clause 3.1 and, to the extent that Medvet has any, comply with any obligations of Medvet under the Bone and Cartilage Licence. 

4. Continuing Obligation. Angioblast acknowledges and agrees that, notwithstanding assignment of the Assigned Technology and
Assigned Materials pursuant to clauses 2.1(a) and 2.2(a) and the Bone and Cartilage Licence pursuant to clause 3.1, from the date of this Deed Mesoblast Limited has agreed with Medvet under the Bone and Cartilage Licence to continue to pay the Bone
and Cartilage Fee pursuant to the Bone and Cartilage Licence directly to Medvet until termination of the Bone and Cartilage Licence. 

5. Cardio Licence and Other Fields. 

(a) Parties acknowledge and agree that the Cardio Licence will terminate with effect from the date of the effective assignment and the grant
of licence (if any) pursuant to clause 2 of this Deed, and notwithstanding termination of the Cardio Licence and in consideration of the assignment and the grant of licence (if any) in clause 2 Angioblast agrees to continue to pay the Cardio Fees to
Medvet after the date of the effective assignment and the grant of licence (if any) pursuant to clause 2 of this Deed. 
 (b) In relation
to the Other Fields (excluding the Cardio Field), and in consideration of the assignment and the grant of licence (if any) under clause 2 Angioblast agrees to pay Medvet the following: 

(i) US$250,000 on completion of a (human) clinical trial phase of any product incorporating the Technology falling within Other Fields
(excluding the Cardio Field) developed solely by Angioblast; 
 (ii) US$350,000 on FDA marketing approval of any product incorporating the
Technology falling within the Other Fields (excluding the Cardio Field) developed solely by Angioblast; 
 payable within 30 days of the
date of the invoice from Medvet for those amounts; and 
 (iii) 2% of Net Sales generated from the sale by Angioblast of products in Other
Fields using or incorporating the Technology, payable each quarter and made in arrears within 30 days of the end of each quarter and accompanied by a written report. 

(c) In this clause, ‘Net Sales’ means the actual sales price (exclusive of any sales or use taxes or value added tax, GST or other
goods and services tax or any other similar 

  
 -11- 

 
taxes imposed on the provision of goods and services to purchasers by the party supplying products using or incorporating the Technology) as invoiced and received by Angioblast from third party
purchasers less discounts, credits and returns on the products using or incorporating the Technology and less freight and handling disbursements, and to the extent that sales are made in any currency other than Australian dollars, the rate of
exchange on the day the products are paid for will be used to convert the Net Sales for those products using or incorporating the Technology to Australian dollars. 

(d) Medvet acknowledges and agrees that: 

(i) Angioblast will not be required to pay any fees under this clause 5 for any Unprotected Country; and 

(ii) if a country becomes an Unprotected Country, Medvet will repay Angioblast any fees paid under this clause 5 for that country from the
date of this Deed up until and including the date that country becomes an Unprotected Country. 
 6. Research Licence. In
consideration for: 
 (a) assignment of the Assigned Technology and Assigned Materials to Angioblast; 

(b) any exclusive licence to Unassignable Technology and Unassignable Materials; and 

(c) any non-exclusive licence to Non-Exclusive Unassignable Materials, 

Angioblast hereby grants Medvet a non-exclusive, perpetual, irrevocable, royalty free licence to use the Technology and Materials for
non-commercial, internal research and academic research effective from the date of this Deed provided Medvet will not use the Technology and Materials commercially or enter contractual obligations with third parties that is either inconsistent with
Angioblast’s rights under this Deed or relates in any way to the Technology and Materials, and further provided that Angioblast will own all research results and Intellectual Property Rights relating thereto developed or created for or on
behalf of Medvet pursuant to Medvet’s licence under this clause 6. 
 7. Warranty. Medvet warrants and it is a condition
of this Deed that: 
 (a) it has good legal and beneficial title to the Technology and Materials, free and clear of all Encumbrances
whatsoever other than the Bone and Cartilage Licence and the PeterMac Research Agreement; 
 (b) it has the right to make the assignments
under clauses 2.1 and 2.2, and to the extent necessary, it has the right to grant the licences (if any) under clauses 2.1 and 2.2; 
 (c)
other than the Bone and Cartilage Licence and the PeterMac Research Agreement, it has not granted any person any right to use or exploit in any way all or any part of the Technology or Materials or to manufacture, market and sell products
incorporating any part of the Technology or Materials in all or any part of the world; 

  
 -12- 

 (d) no person’s consent is required in respect of the assignment or licence of the
Technology and Materials; 
 (e) Medvet is entitled to make all patent applications which it has made in respect to the Technology and
Materials; 
 (f) the assignment to Angioblast of the Assigned Technology and Assigned Materials and any exclusive licence of the
Unassigned Technology and Unassignable Materials and non-exclusive licence of any Non-Exclusive Unassignable Materials, will not infringe any patent, trademark, registered design, copyright or other Intellectual Property Rights of any person, nor
give rise to payment by Angioblast of any royalty or any other payments to any third party or to any liability to pay compensation; 
 (g)
it has Mesoblast Limited’s consent under the Bone and Cartilage Licence to assign the Bone and Cartilage Licence to Angioblast; 
 (h)
it does not require the Peter MacCallum Cancer Institute’s consent under the PeterMac Research Agreement to assign the Assigned Technology and Assigned Materials or to license the Unassignable Technology, Unassignable Materials on an exclusive
basis or to license Non-Exclusive Unassignable Materials on a non-exclusive basis; 
 (i) there is no litigation or claim pending or
threatened, challenging or disputing the ownership or validity of the Technology and Materials or any rights to the Technology and Materials; 

(j) the Bone and Cartilage Licence is valid and subsisting in full force and effect; 

(k) that there is no outstanding breach of the Bone and Cartilage Licence; 

(l) at the date of this Deed, Peter MacCallum Cancer Institute has not approached or provided written notice to Medvet in relation to an
exclusive licence over ‘Background Intellectual Property’ (as defined in the PeterMac Research Agreement) pursuant to clause 9 of the PeterMac Research Agreement; 

(m) at the date of this Deed, Medvet has not given up any rights to obtain patent protection in relation to ‘Future Intellectual
Property’ (as defined in the PeterMac Research Agreement) pursuant to clause 10.5 of the PeterMac Research Agreement, and Medvet will not do so in the future without the prior written consent of Angioblast (such consent to be withheld at the
sole and absolute discretion of Angioblast); and 
 (n) at the date of this Deed, Medvet has not provided any ‘Medvet Funding’
(as defined under the PeterMac Research Agreement) to the Peter MacCallum Cancer Institute pursuant to clause 5 of the PeterMac Research Agreement. 

  
 -13- 

 8. Indemnity. Medvet indemnifies and will keep indemnified Angioblast against all actions,
claims, proceedings, demands, liabilities, losses, damages, expenses and costs (including legal costs on a full indemnity basis) that may be brought against Angioblast or which Angioblast may pay, sustain or incur as a direct or indirect result of
any breach or non-performance of this Deed by Medvet. 
 9. GST. 

(a) In this clause the expressions consideration, GST, input tax credit, recipient, supply, tax invoice and taxable supply have the meanings
given to those expressions in the A New Tax System (Goods and Services Tax) Act 1999 (GST Act). A supplier means any party treated by the GST Act as making a supply under this Agreement. 

(b) Unless otherwise expressly stated, all prices or other sums payable or consideration to be provided under or in accordance with this
Agreement are exclusive of GST. 
 (c) If GST is imposed on any supply made under or in accordance with this Agreement, the recipient of
the taxable supply must pay to the supplier an additional amount equal to the GST payable on or for the taxable supply subject to the recipient receiving a valid tax invoice in respect of the supply at or before the time of payment. Payment of the
additional amount will be made at the same time as payment for the taxable supply is required to be made in accordance with this Agreement. 

10. General. 
 10.1
Nature of obligations. 
 (a) Any provision in this Deed which binds more than one person binds all of those persons jointly and each
of them severally. 
 (b) Each obligation imposed on a party by this Deed in favour of another is a separate obligation. 

10.2 Time of the essence. In this Deed, time is of the essence unless otherwise stipulated. 

10.3 Entire understanding. 

(a) This Deed contains the entire understanding between the parties concerning the subject matter of the agreement and supersedes all prior
communications between the parties, which includes the Material Transfer Agreement executed by the parties dated 7 May 2004. To the extent that there is any inconsistency between that Material Transfer Agreement and this Deed, the provisions of
this Deed will prevail to the extent of such inconsistency. For the avoidance of doubt, the operation of this Deed and its provisions overrides clauses (viii) and (ix) of that Material Transfer Agreement. 

  
 -14- 

 (b) Each party acknowledges that, except as expressly stated in this Deed, that party has not
relied on any representation, warranty or undertaking of any kind made by or on behalf of the other party in relation to the subject matter of this Deed. 

10.4 No adverse construction. This Deed is not to be construed to the disadvantage of a party because that party was responsible
for its preparation. 
 10.5 Further assurances. A party, at its own expense and within a reasonable time of being requested
by another party to do so, must do all things and execute all documents that are reasonably necessary to give full effect to this Deed. 

10.6 No waiver. 
 (a) A
failure, delay, relaxation or indulgence by a party in exercising any power or right conferred on the party by this Deed does not operate as a waiver of the power or right. 

(b) A single or partial exercise of the power or right does not preclude a further exercise of it or the exercise of any other power or right
under this Deed. 
 (c) A waiver of a breach does not operate as a waiver of any other breach. 

10.7 Severability. If any provision of this Deed offends any law applicable to it and is as a consequence illegal, invalid or
unenforceable then: 
 (a) where the offending provision can be read down so as to give it a valid and enforceable operation of a partial
nature, it must be read down to the minimum extent necessary to achieve that result; and 
 (b) in any other case the offending provision
must be severed from this Deed, in which event the remaining provisions of the Deed operate as if the severed provision had not been included. 

10.8 Successors and assigns. This Deed binds and benefits the parties and their respective successors and permitted assigns
under clause 10.9. 
 10.9 No assignment. Medvet cannot assign or otherwise transfer the benefit of this Deed without the
prior written consent of Angioblast. 
 10.10 Consents and approvals Where anything depends on the consent or approval of a party
then, unless this Deed provides otherwise, that consent or approval may be given conditionally or unconditionally or withheld, in the absolute discretion of that party. 

10.11 No variation. This Deed cannot be amended or varied except in writing signed by the parties. 

10.12 Costs. Each party must pay its own legal costs of and incidental to the preparation and completion of this Deed. 

  
 -15- 

 10.13 Duty. 

(a) Any duty (including related interest or penalties) payable in respect of this Deed or any instrument created in connection with it must
be paid by Medvet. 
 (b) Medvet undertakes to keep Angioblast indemnified against all liability relating to the duty, fines and penalties.

 10.14 Governing law and jurisdiction. 

(a) This Deed is governed by and must be construed in accordance with the laws in force in Delaware, USA. 

(b) The parties submit to the exclusive jurisdiction of the courts of Delaware and the USA in respect of all matters arising out of or
relating to this Deed, its performance or subject matter. 
 10.15 Counterparts. If this Deed consists of a number of
signed counterparts, each is an original and all of the counterparts together constitute the same document. 
 10.16 Conflicting
provisions. If there is any conflict between the main body of this Deed and any schedules or annexures comprising it, then the provisions of the main body of this Deed prevail. 

10.17 Non merger. A term or condition of, or act done in connection with, this Deed does not operate as a merger of any of the rights
or remedies of the parties under this Deed and those rights and remedies continue unchanged. 
 10.18 Operation of
indemnities. Unless this Deed expressly provides otherwise: 
 (a) each indemnity in this Deed survives the expiry or
termination of this Deed; and 
 (b) a party may recover a payment under an indemnity in this Deed before it makes the payment in respect
of which the indemnity is given. 
 10.19 No right of set-off. Unless this Deed expressly provides otherwise, a party has no
right of set-off against a payment due to another party. 
 10.20 Relationship of parties. Unless this Deed expressly provides
otherwise, nothing in this Deed may be construed as creating a relationship of partnership, of principal and agent or of trustee and beneficiary. 

  
 -16- 

 Schedule 1 

This Deed Poll is made on:                      day of
                     2004 
 By: [Insert
Name]:                       of 

[Insert Address]:
                                        
                                         
                                         
                   
 (Consenting Party) 

 

			
	In Favour of:		Angioblast Systems, Incorporated of 279 East, 44th Street, New York, NY 10017 United States of America (Angioblast)

 Operative Provisions 

2. The Consenting Party acknowledges that it has moral rights (including rights of integrity, rights of attribution and other rights of an
analogous nature) in part of or all of the Technology and Materials (Works). “Technology” and “Materials” will have the same meaning given to the term in the Intellectual Property Assignment Deed between
Angioblast and Medvet Science Pty Ltd ACN 008 849 745 (Medvet) dated                     2004. 

3. The Consenting Party hereby irrevocably and unconditionally gives its consent, to the fullest extent permitted by law (whether present or
future), pursuant to Part IX of the Copyright Act 1968 (Cth), to Angioblast, its licensees, assignees and successors and their licensees, and other persons authorised by any of them to: 

(a) reproducing, adapting, publishing, performing, exhibiting, communicating or transmitting the Works or any adaptation thereof (or any part
of any of the Works or of any such adaptation) anywhere in the world, in whatever form and in whatever circumstances Angioblast thinks fit including the making of any distortions, additions or alterations to the Works or any adaptation thereof (or
any part of the Works or of such adaptation) as so reproduced, adapted, published, performed, exhibited, communicated or transmitted; and 

(b) reproducing, adapting, publishing, performing, exhibiting, communicating or transmitting the Works or any adaptation thereof (or any part
of any of the Works or of any such adaptation) anywhere in the world without making identification of Angioblast, Medvet, the Institute of Medical and Veterinary Science ABN 35 302 506 443, the Consenting Party or any other person in relation
thereto. 
 4. If any provision of this deed offends any law applicable to it and is as a consequence illegal, invalid or unenforceable
then: 
 (a) where the offending provision can be read down so as to give it a valid and enforceable operation of a partial nature, it must
be read down to the minimum extent necessary to achieve that result; and 

 (b) in any other case the offending provision must be severed from this deed, in which event the
remaining provisions of the deed operate as if the severed provision had not been included. 
 5. This deed is governed by the laws of the
State of Victoria, Australia and the parties submit to the exclusive jurisdiction of the courts of that State. 
 6. The Consenting Party,
at Angioblast’s expense and within a reasonable time of being requested by Angioblast to do so, must do all things and execute all documents that are reasonably necessary to give full effect to this deed. 

7. A failure, delay, relaxation or indulgence by a party in exercising any power or right conferred on the party by this deed does not operate
as a waiver of the power or right. A single or partial exercise of the power or right does not preclude a further exercise of it or the exercise of any other power or right under this deed. A waiver of a breach does not operate as a waiver of any
other breach. 
 Executed as a deed poll. 
  

									
	 Signed Sealed and Delivered by [Insert
		 	)	  				
	 Name]:
                                         
                            in the
		 	)	  				  

	 presence of
		 	)	  				Signature

  

	
	  

	Signature of Witness
	
	  

	Name of Witness
	(Please Print)

  
 -2- 

 Schedule 2 

Essential Materials (clause 2.2(e)) 
 All
hybridomas developed or created by or for IMVS or Medvet, which result in production of monoclonal antibodies reactive with antigens on the surface of mesenchymal precursor cells, or cells of haematopoietic, keratinocyte, or other lineages,
including without limitation, including the following antibodies: 
  

					
	 Clone
	  	 Isotype
	  	 Antigen

			
	CC9	  	IgG2A	  	CD146
			
	EB4	  	IgG1	  	CD146
			
	AC9	  	IgG1	  	CD13
			
	AB11	  	IgG1	  	CD105
			
	XB1	  	IgG1	  	CD105
			
	H8G	  	IgG1	  	CD68
			
	CA12	  	IgG1	  	Alkaline Phosphatase
			
	BB9	  	IgG1	  	ACE
			
	HCC1	  	IgM	  	CD59
			
	MA6	  	?	  	? Megakaryoctes
			
	KF8	  	IgM	  	FUT-1
			
	HYB A	  	IgM	  	? (ANTI-SHEEP)
			
	HYB B	  	IgG1	  	? (ANTI-SHEEP)
			
	HYB C	  	IgM	  	? (ANTI-SHEEP)
			
	HYB D	  	IgM	  	? (ANTI-SHEEP)
			
	HYB E	  	IgM	  	? (ANTI-SHEEP)
			
	HYB F	  	IgM	  	? (ANTI-SHEEP)
			
	HYB G	  	IgM	  	? (ANTI-SHEEP)
			
	HYB H	  	IgG1	  	? (ANTI-SHEEP)
			
	HYB I	  	IgM	  	? (ANTI-SHEEP)

					
	 Clone
	  	 Isotype
	  	 Antigen

			
	CF7.B10	  	IgG1	  	Leptin receptor
			
	CG1 B7	  	IgG1	  	Leptin receptor
			
	7H9	  	IgG1	  	CD44
			
	H9H11	  	IgG1	  	CD44
			
	103B2	  	IgG3	  	CD164
			
	105A5	  	IgM	  	CD164
			
	96.IH5	  	IgG1	  	CD164
			
	96.2D2	  	IgG1	  	CD164
			
	96.3F5	  	IgG2B	  	CD164
			
	96.10H10	  	IgG1	  	CD164
			
	96.12H11	  	IgG1	  	CD164
			
	JP14G12	  	?	  	BETA-1 INTEGRIN
			
	JP15E8	  	?	  	BETA-1 INTEGRIN
			
	JP15F5	  	?	  	BETA-1 INTEGRIN
			
	JP2C5	  	?	  	BETA-1 INTEGRIN
			
	JP4B4	  	?	  	BETA-1 INTEGRIN
			
	JP4B5	  	?	  	BETA-1 INTEGRIN
			
	10G7	  	IgG1	  	Transferrin Receptor

  
 -2- 

 Executed as a deed. 
  

							
	Executed by Medvet Sciences Pty Ltd ABN 15 008 849 745 in accordance with section 127(1) of the Corporations Act 2001 (Cth):		 )
 )

)
 )

)
				
				
	 /s/ (illegible)
						 /s/ Dr. Frances Guyett

	Signature of director						 Signature of director or company secretary*

*delete whichever does not apply

				
	 (illegible)
						 Dr. Frances Guyett

	Name (please print)						Name (please print)
				
	Executed by Angioblast Systems, Incorporated in accordance with its Constitution by its duly authorised officers		 )
 )

)
 )

)
				
	  
						 /s/ Silviu Itescu

	Signature of authorised officer						Signature of authorised officer
				
	  
						 Silviu Itescu

	Name (please print)						Name (please print)

  
 -3-EX-10.16

 Exhibit 10.16 

Deed of Option and Assignment 

Peter MacCallum Cancer Institute 

ABN 42 100 504 883 
 and

 Angioblast Systems, Inc. 

Middletons 
 Melbourne office

 Ref: JGUT:PTH:10005333 

 Deed of Option and Assignment and Termination 

Date 10 August 2010 
 By 

1. Peter MacCallum Cancer Institute ABN 42 100 504 883, a public hospital created by Order pursuant to section 181 of the Health
Services Act 1988 (Vic.) (trading as Peter MacCallum Cancer Centre) of St Andrew’s Place, East Melbourne, Victoria 3002 (PM) 

2. Angioblast Systems, Inc., a Delaware corporation, with its principal office located at 275 Madison Avenue, 4th Floor, New York, NY,
10016 (Angioblast) 
 Background 

A. Medvet and PM are parties to the Agreement. 

B. The Agreement provides that Medvet and PM jointly own certain Intellectual Property Rights. 

C. PM has agreed to grant Angioblast an option to the assignment of PM’s interest in those Intellectual Property Rights on the terms set
out in this Deed. 
 AGREED TERMS 

1. Option. 
 1.1 Grant
of Option. In consideration of the Option Fee, PM grants to Angioblast an option to have assigned to it, subject to clause 1.4, in accordance with this Deed: 

(a) any and all current and future legal and beneficial rights, title and interest in the Assigned IP; 

(b) all rights and immunities relating to, or arising from, the Assigned IP, including all present and past rights to sue for infringement of
the Intellectual Property Rights in the Assigned IP; and 
 (c) to the extent that PM owns or otherwise holds or controls any rights in the
Materials: 
 (i) all Intellectual Property Rights subsisting in the Materials, including all Intellectual Property Rights subsisting in
the composition of matter of the Materials; and 
 (ii) all rights and immunities relating to, or arising from, any of the Intellectual
Property Rights subsisting in the Materials, including all present and past rights to sue for infringement of the Intellectual Property Rights in the Materials, for the Consideration, provided that such option is exercised in accordance with the
terms of this Deed (the “Option”). 

 1.2 Option Fee. 

(a) PM acknowledges receipt of the Option Fee. 

(b) The Option Fee is not refundable. If Angioblast does not exercise the Option the Option Fee is forfeited to PM. 

(c) If the Option is exercised, the Option Fee will be applied as part of the Consideration for the assignment as specified in clause 1.1.

 1.3 Term of the Option. The option shall remain in force and effect during the Option Period. The Option shall lapse at the end of
the Option Period. 
 1.4 Australian and Japanese Patent Rights. 

(a) If Medvet’s consent to the assignment referred to in clause 2.2 is required by law in: 

(i) Australia in relation to the Australian Patent Rights; and / or 

(ii) Japan in relation to the Japanese Patent Rights, 

then the assignment of these Patent Rights under clause 2.2 will be conditional on the consent of Medvet in the jurisdictions where consent
is required, and shall occur automatically upon such consent being obtained. 
 (b) It is the responsibility of Angioblast to obtain the
consent outlined in clause 1.4(a). 
 (c) Nothing in this clause 1.4 affects the Option granted under clause 1.1, or the automatic
assignment upon exercise of the Option under clause 2.2 other than in relation to the Australian and Japanese Patent Rights to the extent the consent of Medvet is required. 

2. Exercising the Option. 

2.1 How to exercise the Option. To exercise the Option, Angioblast must, during the Option Period, deliver to PM an unendorsed bank
cheque payable to PM for the amount of the Consideration. 
 2.2 Automatic Assignment. On exercising the Option, there shall be an
automatic assignment (which shall come into effect without the parties needing to take any action beyond Angioblast making a delivery in accordance with clause 2.3) to Angioblast of all the rights that are the subject of the Option as described in
clause 1. For the avoidance of doubt, PM hereby assigns to Angioblast all such rights, which assignment shall be effective upon the exercise of the Option in accordance with clause 2.1. 

  
 -2- 

 2.3 Delivery of the Assigned IP. Within 5 Business Days of Angioblast making a delivery in
accordance with clause 2.1, PM must, except where contrary to the Agreement to do so, deliver to Angioblast: 
 (a) all tangible
embodiments of the Assigned IP; 
 (b) all documents evidencing ownership of the Assigned IP (including all copies retained for the
purposes of legal proceedings) and/or the Materials and/or the use thereof that is in its possession; 
 (c) all the Materials in its
possession or control; and 
 (d) all antibodies or portion thereof produced or expressed by any of the Materials. 

3. Extending the Option Period. Angioblast may extend the Option Period by the Extension Period if, before the Option Period ends,
Angioblast delivers to PM an unendorsed bank cheque payable to PM for the Extension Fee. 
 4. Confirmation. PM confirms that it only
has such right, title or interest in the Materials and the Intellectual Property Rights therein, to the extent granted by the Agreement and the Patent Rights and confirms that to the extent that it does have such right, title or interest in the
Materials and the Intellectual Property Rights therein, PM has granted Angioblast an option to an assignment of these under clause 1.1(c). 

5. Obligations during the Option Period and any Extension Period. During the Option Period and any Extension Period, PM agrees to: 

(a) provide to Angioblast all patent notices, correspondence and documentation regarding the Assigned IP and the Materials that it receives
and distributes; 
 (b) consult with Angioblast before making any amendments to claims of the Patent Rights and have regard to
Angioblast’s comments and suggestions in instructing PM’s appointed patent attorneys during the Option Period and any Extension Period; and 

(c) consult with Angioblast with respect to any litigation for infringement of or defence of the Assigned IP and subject to the agreement of
Medvet take all reasonable action in protecting the interests of Angioblast and PM. 
 6. Further acts. 

(a) Upon the Option being exercised in accordance with clause 2, PM appoints from that date Angioblast as its attorney to do all acts and
execute all documents on behalf of PM to the extent necessary to vest the rights in Angioblast as contemplated by this Deed. 

  
 -3- 

 (b) Upon the Option being exercised in accordance with clause 2, PM agrees to execute all such
further documents and do all such further acts necessary to effect the assignment of the Intellectual Property Rights in the Assigned IP and the Materials to Angioblast. 

(c) Angioblast shall reimburse PM for all out of pocket expenses incurred by PM in complying with clause 6(b). 

7. Warranties. PM warrants and it is a condition of this Deed that: 

(a) it has good legal and beneficial title to the Assigned IP; 

(b) it has the right to grant the Option under clause 1; 

(c) other than in relation to the Australian and Japanese Patent Rights to the extent the consent of Medvet is required by Australian and
Japanese law respectively, it has the right to assign the rights that are the subject of the Option under clause 2.2 and no other person’s consent is required in respect of the assignment of the Assigned IP or of the rights assigned under
clause 2.2; 
 (d) to the best of its actual knowledge at the date of this Deed, Angioblast’s use of the Assigned IP or of the rights
that may be assigned under clause 2.2 will not infringe any third party’s rights (including Intellectual Property Rights); 
 (e)
prior to the date of this Agreement, PM has given Angioblast a true, complete and, where applicable, duly executed copy of the; 
 (i) 2007
Deed of Assignment; and 
 (ii) Settlement Deed between PM and the Australian Stem Cell Centre Limited ACN 101 957 251 (“ASCC”).

 and PM warrants that these documents are unamended and still in force. 

8. No further claims. PM acknowledges that upon exercise of the Option under clause 2 and subject to the payment of the Consideration
and the assignment of the Assigned IP and the Intellectual Property Rights in the Materials, PM has no further rights (including Intellectual Property Rights or otherwise) to ownership of the Assigned IP or to the Intellectual Property Rights in the
Materials and will make no further claim of whatsoever nature for monetary compensation or otherwise against Angioblast in relation to the Assigned IP or the Materials or the past or future use of the Assigned IP or of the Intellectual Property
Rights in the Materials by Angioblast. 
 9. GST. 

9.1 Definitions. In this clause 9: 

  
 -4- 

 (a) the expressions Consideration, GST, Input Tax Credit, Recipient,
Supply, Tax Invoice and Taxable Supply have the meanings given to those expressions in the A New Tax System (Goods and Services Tax) Act 1999 (GST Act); and 

(b) Supplier means any party treated by the GST Act as making a Supply under this Deed. 

9.2 Consideration is GST exclusive. Unless otherwise expressly stated, all prices or other sums payable or Consideration to be provided
under or in accordance with this Deed are exclusive of GST. 
 9.3 Payment of GST. 

(a) If GST is imposed on any Supply made under or in accordance with this Deed, the Recipient of the Taxable Supply must pay to the Supplier
an additional amount equal to the GST payable on or for the Taxable Supply, subject to the Recipient receiving a valid Tax Invoice in respect of the Supply at or before the time of payment. 

(b) Payment of the additional amount must be made at the same time and in the same way as payment for the Taxable Supply is required to be
made in accordance with this Deed. 
 9.4 Reimbursement of expenses. If this Deed requires a party (the First Party) to pay
for, reimburse, set off or contribute to any expense, loss or outgoing (Reimbursable Expense) suffered or incurred by the other party (the Other Party), the amount required to be paid, reimbursed, set off or contributed by the First
Party will be the sum of: 
 (a) the amount of the Reimbursable Expense net of Input Tax Credits (if any) to which the Other Party is
entitled in respect of the Reimbursable Expense (Net Amount); and 
 (b) if the Other Party’s recovery from the First Party is
a Taxable Supply, any GST payable in respect of that Supply, 
 such that after the Other Party meets the GST liability, it retains the Net
Amount. 
 10. Termination of Agreement. 

(a) PM confirms that it and its Scientists (as defined in the Agreement) no longer require the licence to the Background Intellectual
Property (as defined in the Agreement) granted to PM under the Agreement. 
 (b) PM warrants that it jointly owns the Assigned IP as
tenants-in-common with Medvet and the Assigned IP is the only Future Intellectual Property arising out of the Agreement. 

  
 -5- 

 (c) In the event that Medvet consents to the termination of the Agreement, PM agrees to
terminate the Agreement within fourteen days of a request to do so by Angioblast. 
 (d) Notwithstanding any statement to the contrary in
the Agreement, PM agrees that where the Agreement is terminated, the last sentence of clause 19.1.2 of the Agreement will be of no force and effect from the date of termination in relation to the Assigned IP and the Materials. 

(e) This Clause 10(c) will survive termination of this Deed. 

(f) Upon Medvet consenting to the termination of the Agreement, PM: 

(i) appoints Angioblast as its attorney to do all acts and execute all documents on behalf of PM to the extent necessary to give effect to
the termination; 
 (ii) agrees to execute all such further documents and do all such further acts necessary to effect the termination of
the Agreement; and 
 (iii) automatically assigns to Angioblast all necessary documentation to give effect to the termination to
Angioblast. 
 11. General. 

11.1 Nature of obligations. 

(a) Any provision in this Deed which binds more than one person binds all of those persons severally not jointly. 

(b) Each obligation imposed on a party by this Deed in favour of another is a separate obligation. 

11.2 No adverse construction. This Deed is not to be construed to the disadvantage of a party because that party was responsible for
its preparation. 
 11.3 Further assurances. A party, at its own expense and within a reasonable time of being requested by another
party to do so, must do all things and execute all documents that are reasonably necessary to give full effect to this Deed. 
 11.4
Severability. If any provision of this Deed offends any law applicable to it and is as a consequence illegal, invalid or unenforceable then: 

(a) where the offending provision can be read down so as to give it a valid and enforceable operation of a partial nature, it must be read
down to the minimum extent necessary to achieve that result; and 

  
 -6- 

 (b) in any other case the offending provision must be severed from this Deed, in which event the
remaining provisions of the Deed operate as if the severed provision had not been included. 
 Notwithstanding anything to the contrary in
this Agreement, the parties acknowledge and agree that the rights conferred on, and assignments in favour of, Angioblast under this Agreement exclude any such rights and assignments that are unlawful, which unlawfulness shall be considered in
respect of each member patent and member patent application of the Patent Rights separately. 
 11.5 Confidentiality. 

(a) Obligations of confidentiality 

Each party (Receiving Party) receiving, possessing or otherwise acquiring Confidential Information of any other party (Disclosing
Party) acknowledges that the Disclosing Party’s Confidential Information is the property of and confidential to or a trade secret of the Disclosing Party. Subject to clause 11.5(b), the Receiving Party must: 

(i) keep the Disclosing Party’s Confidential Information confidential and not directly or indirectly disclose, divulge or communicate
that Confidential Information to, or otherwise place that Confidential Information at the disposal of, any other person without the prior written approval of the Disclosing Party; 

(ii) take all reasonable steps to secure and keep secure all Disclosing Party’s Confidential information coming into its possession or
control; and 
 (iii) not memorise, use, modify, reverse engineer or make copies, notes or records of the Disclosing Party’s
Confidential Information for any purpose other than in connection with the performance by the Receiving Party of its obligations under this Agreement. 

(b) Exceptions 
 (i) The
obligations of confidentiality (other than as provided under clause 11.5(b)(ii)) under clause 11.5(a) do not apply to any information that: 

(A) is generally available to the public (other than by reason of a breach of this Agreement); or 

(B) is required to be disclosed by any applicable law. 

(ii) The terms of this Deed are confidential to the parties and must not be disclosed directly or indirectly, in whole or in part, by any
party unless the disclosure is: 
 (A) to enforce this Deed; 

  
 -7- 

 (B) required by law including any required announcement to a stock exchange; 

(C) made to a party’s insurers, legal advisers or auditors, in each case on a confidential basis; or 

(D) in the case of Angioblast, in dealings with Medvet and the Central North Adelaide Health Service ABN 18 348 214 208, an incorporated
hospital under the Health Care Act 2008 (SA). 
 11.6 Successors and assigns. This Deed binds and benefits the parties
and their respective successors and permitted assigns. 
 11.7 No assignment. PM shall not assign or otherwise transfer the benefit
of this Deed without the prior written consent of Angioblast. 
 11.8 No variation. This Deed cannot be amended or varied except in
writing signed by the parties. 
 11.9 Costs. Each party must pay its own legal costs of and incidental to the preparation and
completion of this Deed. 
 11.10 Governing law and jurisdiction 

(a) This Deed is governed by and must be construed in accordance with the laws in force in Victoria. 

(b) The parties submit to the exclusive jurisdiction of the courts of that State and the Commonwealth of Australia in respect of all matters
arising out of or relating to this Deed, its performance or subject matter. 
 11.11 Counterparts. If this Deed consists of a number
of signed counterparts, each is an original and all of the counterparts together constitute the same document. 

  
 -8- 

 Schedule 1 - Dictionary 

In this Deed, 
 2007 Deed of Assignment
means the Deed of Assignment between Medvet and PM dated 11 September 2007; 
 Agreement means the Licence Agreement between
Medvet and PM dated on or about 1 October 1999; 
 Assigned IP means all of PM’s right, title and interest, including all
Intellectual Property Rights in the Invention and Patent Rights; 
 Business Day means a day which is not a Saturday, Sunday, public
holiday or bank holiday in Melbourne; 
 Confidential Information means all information belonging or relating to a party to this
Agreement, whether oral, graphic, electronic, written or in any other form, that is not generally available to the public at the time of disclosure other than by reason of a breach of this Agreement or that is in fact, or should reasonably be
regarded as, confidential to the party to whom it belongs or relates, including this Deed and the existence of this Deed; 

Consideration means AUD$150,000 less: 

(a) the Option Fee, being a total of $138,000; or 

(b) in circumstances where the option is extended by the Extension Period in consideration for the Extension Fee in accordance with clause 3,
less the Option Fee and the Extension Fee, being a total of $132,000; 
 Deed means this deed and any Schedule together with any
annexures; 
 Future Intellectual Property has the meaning ascribed to it in the Agreement; 

Extension Fee means the amount of AUD$6,000; 

Extension Period means the period of 6 months; 

GST has the meaning given to that expression in the A New Tax System (Goods and Services Tax) Act 1999
(Cth); 
 Intellectual Property Rights means all intellectual property rights conferred by statute, at common law or in equity
and wherever existing, including: 
 (c) patents, designs, copyright, rights in circuit layouts, plant breeder’s rights, trade marks,
know how, brand names, domain names, inventions, product names, trade secrets and any other rights subsisting in the results of intellectual effort in any field, whether or not registered or capable of registration; 

  
 -9- 

 (d) any application or right to apply for registration of any of these rights; 

(e) any registration of any of those rights or any registration of any application referred to in paragraph (d); and 

(f) all renewals and extensions of these rights; 

Invention means a novel means of identifying specific populations of cell types with the use of an antibody known as BB9, for the
identification and isolation of stem cells; 
 Materials means hybridomas that express the BB9 antibody and all cells and cell lines
that have been engineered to express the BB9 antibody or any portion thereof and all parent, sister and sub-clone hybridoma cell lines and any cell or cell line into which the DNA from a hybridoma expressing the BB9 antibody or any portion thereof
has been transfected (whether stably or otherwise) or otherwise transferred and all byproducts and derivatives of the foregoing biological materials; 

Medvet means Medvet Science Pty Ltd ACN 008 089 746; 

Option has the meaning specified in clause 1.1; 

Option Fee means the amount of $12,000 and includes the Extension Fee if Angioblast extends the Option Period under clause 3; 

Option Period means the period of time commencing on the date of this Deed and expiring 12 months thereafter, unless extended under
clause 3, in which case the period shall expire in accordance with clause 3; 
 Patent Application means a patent application as
defined in the Patents Act 1990 and any national, regional or international application for a patent (whether under the Patent Co-operation Treaty or not). It includes a continuation, continuation in part, division, re-issue or
substitution of a patent application or application for a substantially similar form of protection for an invention granted by another country where the essence is that the holder of the protection gains an exclusive right to make, use and sell a
product or process which is the subject of that invention; 
 Patent means a patent as defined in the Patents Act 1990 and any
national or regional patent (whether under the Patent Co-operation Treaty or not). It includes a re-issue, renewal or extension of a patent (whether in whole or in part) and a patent of addition or a substantially similar form of protection
for an invention granted by another country where the essence is that the holder of the protection gains an exclusive right to make, use and sell a product or process which is the subject of that invention; 

Patent Rights means the Patents and Patent Applications identified in Schedule 2; and 

Schedule means a schedule to this Deed. 

  
 -10- 

 Schedule 2 

List of Patent Rights 
 Granted
Patents: 
 Australia(No: AU2002355970) 

USA(No: 10/486845) Notice of Allowance granted by USPTO on 30 November 2009 

Patent Applications: 
 Israel (No:160394) 

Europe(No: 02750673.2) 

Japan(No: 2003521372) 

Canada(No: 2457632) 
 _the
Australian Provisional Patent PR7036 filed on 15 August 2001; and 
 International Patent Application PCT/AU2002/001101 (No:
WO/2003/016916) filed on 15 August 2002 entitled “Identification and Isolation of Somatic Stem Cells and uses thereof” and any letters patent subsequently granted in respect of such Application and any further corresponding patent
application filed by PM or PM and other joint owner, Medvet in any country of the world. 

  
 -11- 

 EXECUTED and delivered as a deed in Melbourne 

 

							
	 Signed Sealed and Delivered by the authorised

representative of Peter MacCallum Cancer Institute

ABN 42 100 504 883 trading as Peter MacCallum
 Cancer
Centre in the presence of:
		 )
 )

)
 )

)
				
	 /s/ Les Manson
						 /s/ Craig Bennett

	Signature of witness						Signature of authorised representative By executing this agreement the representative states that they have received no notice that their authority to do so has been revoked.
	 Les Manson
						 C. A Bennett

	 Name of witness
 (please print)
						 Name of authorised representative
 (please
print)

				
	Signed Sealed and Delivered for and on behalf of Angioblast Systems Inc. in accordance with its Constitution by its duly authorised representative in the presence of:		 )
 )

)
 )
				 CEO, Peter Mac
 23 July, 2010

	 /s/ Kate O’Callahan
						 /s/ Silviu Itescu

	Signature of witness						 Signature of authorised representative
 By
executing this agreement the representative states that they have received no notice that their authority to do so has been revoked.

	 Kate O’Callahan
						 Silviu Itescu

	 Signature of witness
 (please print)
						 Name of authorised representative
 (please
print)
 Executive Director
 10 August 2010

  
 -12-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00250-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00250-of-00352.parquet"}]]